- Home
- RVSB vs EDIT Comparison
RVSB vs EDIT Comparison
Compare RVSB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- EDIT
- Stock Information
- Founded
- RVSB 1923
- EDIT 2013
- Country
- RVSB United States
- EDIT United States
- Employees
- RVSB N/A
- EDIT N/A
- Industry
- RVSB Savings Institutions
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVSB Finance
- EDIT Health Care
- Exchange
- RVSB Nasdaq
- EDIT Nasdaq
- Market Cap
- RVSB 122.2M
- EDIT 108.1M
- IPO Year
- RVSB 1993
- EDIT 2016
- Fundamental
- Price
- RVSB $6.09
- EDIT $1.18
- Analyst Decision
- RVSB
- EDIT Buy
- Analyst Count
- RVSB 0
- EDIT 14
- Target Price
- RVSB N/A
- EDIT $8.08
- AVG Volume (30 Days)
- RVSB 74.2K
- EDIT 2.0M
- Earning Date
- RVSB 04-24-2025
- EDIT 03-05-2025
- Dividend Yield
- RVSB 1.30%
- EDIT N/A
- EPS Growth
- RVSB N/A
- EDIT N/A
- EPS
- RVSB 0.04
- EDIT N/A
- Revenue
- RVSB $46,646,000.00
- EDIT $32,314,000.00
- Revenue This Year
- RVSB $4.26
- EDIT N/A
- Revenue Next Year
- RVSB $8.70
- EDIT N/A
- P/E Ratio
- RVSB $165.07
- EDIT N/A
- Revenue Growth
- RVSB N/A
- EDIT N/A
- 52 Week Low
- RVSB $3.30
- EDIT $1.12
- 52 Week High
- RVSB $6.38
- EDIT $7.09
- Technical
- Relative Strength Index (RSI)
- RVSB 81.93
- EDIT 40.57
- Support Level
- RVSB $5.43
- EDIT $1.24
- Resistance Level
- RVSB $5.60
- EDIT $1.32
- Average True Range (ATR)
- RVSB 0.18
- EDIT 0.09
- MACD
- RVSB 0.08
- EDIT -0.03
- Stochastic Oscillator
- RVSB 75.83
- EDIT 15.79
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.